Ectica and SCREEN to Present Collaborative Work at the AACR 2022 Meeting
Ectica Technologies AG and SCREEN Holdings Co Ltd. will be exhibiting together at the American Association for Cancer Research (AACR) 2022 annual meeting. The event will be held from April 8 to April 13 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
About the AACR Annual Meeting 2022 – New Orleans
The American Association for Cancer Research (AACR) Annual Meeting is at the center of the cancer research community, bringing together scientists, clinicians, medical professionals, survivors, patients, and supporters to discuss the most recent developments in cancer science and therapy. The work of the brightest minds in cancer research from institutions all around the world is highlighted at the AACR Annual Meeting.
Tomographic imaging of organotypic cultures developed in the 3DProSeed hydrogel plate
Ectica Technologies and SCREEN will present their collaborative work on label-free 3D tomographic imaging of organotypic cultures grown on the 3DProSeed hydrogel plate. In the realm of oncology research and diagnostics, the use of advanced ex vivo human organotypic cultures is quickly expanding, with an emphasis on patient-derived organoids and tumor tissue specimens cultivated in artificial systems capable of replicating tumor development mechanisms. These mechanisms include metastasis, angiogenesis and formation of dysplasia. The companies aim to enhance the label-free imaging and analytical capabilities of these complex tissue samples to enable screening and diagnostics applications.
About the SCREEN Holdings Co. Ltd technology
SCREEN Holdings Co Ltd has developed an unparalleled infrared laser-based optical coherence tomography (technology equipped with an 890 nm center wavelength) light from a super luminescent diode and an objective (NA=0.3 high magnification lens), thereby, facilitating non-invasive, label-free, three dimensional 3D) imaging of tumoroids, epithelial cystic organoids, sprouting endothelial neo vasculature and metastatic single cells. SCREEN present culture and imaging protocols with the resulting 3D tomographic reconstructions of endothelial sprouting vessels, cystic epithelial organoids of the colon and 3D invasion assays of highly metastatic glioma cells.
About Ectica Technologies and the 3DProSeed hydrogel plate
The 3DProSeed hydrogel plate developed by Ectica Technologies provides the highest workflow integration in screening processes. There is no need to assemble the hydrogels since they are pre-cast in the plate and delivered hydrated and ready for cell seeding. No cell encapsulation procedures are required thanks to the patented hydrogel surface. In addition, the hydrogels, made of poly(ethylene glycol)-based bioconjugates, are fully synthetic and animal free and offer the highest control over the culture conditions, as well as the possibility to upgrade to GMP for cell therapy applications. Lastly, various cell populations can be sequentially seeded at different time points to generate complex co-cultures. Through this mechanism, stromal environments can be created under controlled conditions, to which cancer cells can be subsequently added.
